tradingkey.logo

BRIEF-Springworks Therapeutics Announces FDA Approval Of Gomekli (Mirdametinib) For Treatment Of Adult And Pediatric Patients With NF1-PN

ReutersFeb 11, 2025 10:48 PM

- SpringWorks Therapeutics Inc SWTX.O:

  • SPRINGWORKS THERAPEUTICS ANNOUNCES FDA APPROVAL OF GOMEKLI™ (MIRDAMETINIB) FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN

Source text: ID:nGNX2JBPk7

Further company coverage: SWTX.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI